PepGen is committed to transforming the treatment for people living with Duchenne muscular dystrophy (DMD) with our Enhanced Delivery Oligonucleotides (EDOs).
Oligonucleotides are genetic medicines that have the potential to modify the root cause of numerous neuromuscular disorders. Oligonucleotides for the treatment of DMD include exon skipping drugs. Some countries have approved exon skipping drugs for the treatment of DMD.
However, oligonucleotides, on their own, do not enter muscles easily, which limits their potential efficacy. For this reason, PepGen has developed peptides that can be conjugated (connected) to oligonucleotides, to enhance and improve their delivery and therefore their activity.
Preclinical research of our EDOs showed high levels of dystrophin production in animals.
In our Phase 1 clinical study in healthy volunteers, we observed high levels of oligonucleotides and exon skipping in muscle.
Most recently, we reported encouraging initial results from the low dose cohort of our CONNECT1-EDO51 Phase 2 trial. The results support that PGN-EDO51 delivered oligonucleotides to the nucleus of muscle cells – the site of action.
See our FAQ for additional resources and information.